Urolithin A is a compound your gut bacteria produce when you consume foods rich in ellagitannins: pomegranates, certain berries, and walnuts among them. It has attracted scientific attention primarily for its ability to activate mitophagy, the cellular process that identifies and clears out worn-out mitochondria and makes room for healthier replacements. As interest in supplementation has grown, one of the most common practical questions is straightforward: how much urolithin A per day is actually supported by evidence?
The honest answer is that human research on this compound is still early-stage. A small number of clinical trials have tested specific doses for safety and biological effect, but large-scale, long-term dose-response studies are lacking. This article walks through what those studies found, where the evidence runs out, and what that means for anyone considering urolithin A supplementation.
Key Takeaways
- The primary human clinical trial tested 500 mg and 1000 mg daily doses and found both safe and biologically active, with plasma acylcarnitines and muscle mitochondrial gene expression changing at both doses; these were secondary outcomes [1].
- Urolithin A activates mitophagy, the cellular process that clears damaged mitochondria, meaning effective dosing is tied to reaching concentrations that meaningfully engage this pathway.
- Food-derived urolithin A is highly variable: gut microbiome composition determines how much ellagitannins are converted, making direct supplementation the more consistent delivery route.
- Dose-dependent relationships between ellagitannin intake and urolithin metabolite levels have been confirmed in dietary research [2], supporting the biological plausibility of dose-response effects.
- Long-term dose-response data in humans is lacking; current evidence supports short-term safety at 500 to 1000 mg but cannot establish an optimal dose for extended use.
Why Dosage Matters: The Mitophagy Mechanism
Mitochondria, the organelles that generate energy inside your cells, accumulate damage over time. Cells have a quality-control process called mitophagy that tags dysfunctional mitochondria for removal and recycling. When this process slows down, damaged mitochondria linger, contributing to the energy deficits and cellular dysfunction associated with aging.
Urolithin A appears to work primarily by upregulating this mitophagy process. At effective concentrations, it activates molecular pathways that improve the tagging and clearance of damaged mitochondria, which may in turn support the renewal of the mitochondrial pool and overall cellular energy capacity. The dose you take determines whether urolithin A reaches the tissue concentrations needed to meaningfully activate these pathways, which is why the question of dosage is biologically substantive, not just a marketing decision.
Understanding this mechanism also clarifies the limits of current evidence: researchers can measure whether a dose activates mitophagy-related gene expression, but translating that into specific functional outcomes (like muscle strength, endurance, or long-term health markers) requires much larger and longer trials than have been completed to date.
The Key Human Clinical Trial: What Doses Were Tested?
The most directly relevant human data comes from a first-in-human study published in Nature Metabolism, which assessed urolithin A supplementation in healthy older adults across multiple dose levels, including 500 mg and 1000 mg per day over a four-week period [1]. Researchers measured safety, tolerability, and molecular markers of mitochondrial and cellular health, including gene expression related to mitophagy and mitochondrial biogenesis.
Human trials mostly tested 500 mg or 1,000 mg of urolithin A a day
The human record covers 500 mg and 1,000 mg a day; nothing here shows which dose, if any, gives a benefit.
Each bar is the daily dose in one human trial. Trials differed in length, age group and outcomes, so bars are not a dose-response curve. Source: Singh et al., Cell Reports Medicine 2022; Liu et al., JAMA Network Open 2022; Denk et al., Nature Aging 2025; Monsalve Acevedo et al., Frontiers in Nutrition 2025; Kuerec et al., Ageing Research Reviews 2024.
Data table
| Item | Value |
|---|---|
| 4-month trial, 88 middle-aged adults (low dose) | 500 mg |
| 4-month trial, 88 middle-aged adults (high dose) | 1000 mg |
| 4-month trial, 66 adults aged 65 to 90 | 1000 mg |
| 4-week immune trial, 50 middle-aged adults | 1000 mg |
| 6-week pilot, 20 male academy soccer players | 1000 mg |
| Lowest dose in a review of five studies (range 10 to 1000 mg) | 10 mg |
Chart: urolithinhub.com: Human trials mostly tested 500 mg or 1,000 mg of urolithin A a day
Embed this chart
Free to reuse on your site. Copy the code below; please keep the credit link.
Research note: A systematic review of five human studies (250 healthy people, 10 to 1000 mg/day for 28 days to 4 months) found a dose-dependent anti-inflammatory effect and some upregulated mitochondrial genes, but no effect on maximal mitochondrial ATP production, biogenesis, dynamics or gut microbiota composition [8].
The trial reported a favourable safety profile at the doses tested, which was its primary outcome [1]. [1]. Crucially, it also induced a molecular signature consistent with improved mitochondrial function: showing that urolithin A was bioavailable in plasma at every dose tested and shifted some biomarkers; these were secondary outcomes, so they are signals rather than proof of benefit [1]. This was a significant finding because it validated that the compound is orally bioavailable and biologically active at realistic supplement doses.
500 mg vs 1000 mg: Is There a Dose-Response Effect?
Within the range studied in [1], there was a signal suggesting that higher doses produced more pronounced molecular changes. Both 500 mg and 1,000 mg changed plasma acylcarnitines and muscle mitochondrial gene expression. In the later middle-aged trial, acylcarnitines fell at 500 mg but not at 1,000 mg, so that biomarker showed no dose-response [1][6]. However, the study was not sized or designed to determine whether this molecular difference translates into meaningful differences in functional outcomes such as physical performance or metabolic health markers.
This dose-response relationship is consistent with findings from dietary ellagitannin research more broadly. A study using standardized black raspberry food products, which are rich in ellagitannin precursors that gut bacteria convert into urolithin metabolites, found dose-dependent increases in ellagitannin metabolites in participants consuming larger amounts, confirming that higher intake leads to proportionally greater urolithin-type metabolite production [2]. Whether the same linear relationship holds for direct urolithin A supplementation across a wider dose range in humans remains an open question.
In practical terms, the current evidence supports both 500 mg and 1000 mg as biologically active and safe doses, with both doses changing some biomarkers in the first-in-human trial [1][6]. There is no published human data supporting doses substantially above this range.
The later four-month trials of 500 and 1,000 mg in middle-aged adults and 1,000 mg in older adults both missed their primary endpoints, and both were funded by Amazentis, the maker of Mitopure [6][7].
Dietary Sources: Can Food Alone Provide Effective Amounts?
Urolithin A is not found pre-formed in food in meaningful quantities. It is produced by gut bacteria acting on ellagitannin precursors found in pomegranate, certain berries, walnuts, and some other plant foods. The amounts generated from food depend on what you eat, how consistently you eat it, and, critically, which gut microbes you carry.
Research on specific food sources confirms that dietary ellagitannins can reach urolithin-producing pathways. A study using watermelon juice enriched with pomegranate ellagitannins found measurable urolithin metabolites in participants and observed effects on metabolism during physical exercise [3]. More recently, a crossover clinical trial found that acid hydrolysis of jaboticaba peel and seed powder, a preparation that increases ellagitannin bioavailability, led to increased urolithin excretion in healthy participants [4]. These findings confirm food-derived ellagitannins can contribute to urolithin exposure, though amounts generated are generally lower and more variable than what is delivered by direct supplementation.
Mediterranean dietary patterns, which include polyphenol-rich foods such as pomegranate and berries among many other plant sources, have been associated with favorable cardiovascular markers in large epidemiological work [5]. Whether urolithin A specifically drives any part of that association, or whether it reflects the broader polyphenol portfolio, has not been established.
Individual Variation: Why One Dose Does Not Fit All
One of the most important factors in urolithin A biology is gut microbiome composition. The bacteria that convert dietary ellagitannins into urolithin A are not universally present, and research has found that a substantial portion of people produce little to no urolithin A from ellagitannin-rich foods, even after consuming significant amounts of pomegranate or berry products. This makes food-based urolithin A delivery highly unpredictable across individuals.
Direct supplementation with urolithin A bypasses this gut conversion step entirely, delivering the active compound without dependence on microbiome composition. This is a genuine practical advantage for people who are non-producers or low producers from diet. However, individual differences in intestinal absorption, hepatic metabolism, and tissue uptake still exist, and the human trials conducted so far have been in relatively small, defined populations: limiting confident generalizations across diverse groups.
When to Take Urolithin A: Timing and Absorption
The timing of urolithin A supplementation is an area that has received less direct research than dosage, but some general principles of nutrient absorption can apply. Urolithin A supplements are typically taken orally, and their absorption can be influenced by the presence of food.
Most manufacturers recommend taking urolithin A with a meal or a healthy fat source. This is because urolithin A is a lipophilic (fat-soluble) compound, and consuming it with food, particularly fats, can enhance its absorption and bioavailability. Taking it with a meal can also help mitigate any potential minor gastrointestinal discomfort, although this is rare with urolithin A.
Consistency is often more important than precise timing for supplements that work by modulating cellular processes. Establishing a routine, such as taking it with breakfast or dinner, ensures regular intake and allows the body to maintain steady levels of the compound. There is no current evidence suggesting a specific time of day (morning vs. evening) offers superior benefits.
Safety Profile and Potential Side Effects
Urolithin A has demonstrated a favorable safety profile in human clinical trials conducted to date. Doses up to 1,000 mg per day are the highest tested in the published human trials, and were well tolerated; a systematic review of five trials in 250 people reported adverse events that were mild or moderate and judged unrelated to treatment.[1][8] In the four-month middle-aged trial, 102 adverse events were reported by 45 participants, including 42 events in 17 placebo participants, and the authors judged urolithin A safe and well tolerated [6].
These mild symptoms are typically transient and can often be alleviated by taking the supplement with food. It is crucial to adhere to recommended dosages and consult with a healthcare professional before starting any new supplement, especially if you have pre-existing medical conditions or are taking other medications. There is currently limited data on urolithin A use in pregnant or breastfeeding women, and caution is advised in these populations.
As a postbiotic, urolithin A’s production relies on a healthy gut microbiome. While direct supplementation bypasses the need for specific gut bacteria, maintaining a diverse and healthy gut flora is beneficial for overall health and may complement urolithin A’s actions. No significant drug interactions have been identified, but vigilance is always recommended.
What the Evidence Supports, and Where It Ends
The clearest evidence-based statement that can be made about urolithin A dosage is this: 500 mg to 1000 mg per day has been tested in adult humans, found to be safe over a four-week period, and shown to change some biomarkers of mitochondrial health at both doses, as secondary outcomes [1][6]. Commercial supplements are generally formulated within this studied range.
What the evidence cannot currently support: optimal dosing for specific populations (older adults vs younger, athletes vs sedentary individuals), long-term safety beyond short study periods, or dose thresholds tied to specific functional outcomes. No regulatory body has established a recommended daily intake. The current evidence base is promising but genuinely preliminary, and it is worth holding that framing when evaluating supplement marketing claims.
đź›’ Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day: The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10): adds resveratrol and CoQ10, a combination the published urolithin A trials did not test. - ProHealth Longevity Urolithin A
capsules, 500 mg: Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg: Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The human clinical evidence on urolithin A dosage is limited in scale and duration; existing trials are small and measured biomarkers rather than long-term health outcomes, so no firm dosage recommendations can be made. Anyone with underlying health conditions, those who are pregnant or breastfeeding, or those taking medications should consult a qualified healthcare provider before starting any new supplement.
Frequently Asked Questions
What is the recommended dose of urolithin A per day?
There is no officially established recommended dose. The most relevant human trial tested 500 mg and 1000 mg daily and found both safe and biologically active over four weeks, with changes in some mitochondrial biomarkers at both doses [1][6]. Most commercial supplements are formulated within this studied range.
Is 500 mg of urolithin A per day enough to have an effect?
In the key human clinical trial, 500 mg per day changed plasma acylcarnitines and muscle mitochondrial gene expression (secondary outcomes) and was reported to have a favourable safety profile [1]. Whether 500 mg is sufficient for a given individual’s goals cannot be answered definitively by the current evidence, but it falls within the range where biological activity has been demonstrated.
Can you get enough urolithin A from eating pomegranate?
Pomegranate is rich in ellagitannins, which gut bacteria convert into urolithin A. Research combining pomegranate ellagitannins with other sources found measurable urolithin metabolites and effects on exercise metabolism [3]. However, the amount produced depends heavily on your gut microbiome, and many people do not carry bacteria efficient enough to generate amounts comparable to direct supplementation.
Is urolithin A safe to take daily?
The published first-in-human trial found urolithin A supplementation at 500 to 1000 mg per day to be safe and well tolerated over a four-week study period, with no serious adverse events [1]. Long-term safety data beyond short trial periods is limited, so extended use warrants appropriate caution and ideally medical guidance.
Does taking more urolithin A produce a stronger effect?
Within the doses studied, both 500 mg and 1,000 mg changed some mitochondrial biomarkers, and the later middle-aged trial found no dose-response for acylcarnitines [1]. Research on ellagitannin precursors also confirms dose-dependent increases in urolithin metabolites with higher dietary intake [2]. Whether this translates to meaningfully better functional outcomes at 1000 mg versus 500 mg has not been demonstrated in human trials.
Why do some people seem to respond more than others?
When consuming dietary sources of ellagitannins, gut microbiome composition is the dominant variable: people without the relevant bacteria produce little or no urolithin A from food, regardless of how much they eat. Direct supplementation bypasses this conversion step. Even so, individual differences in absorption and metabolism mean response to supplementation is unlikely to be uniform, though the research to characterize this variability in humans is still limited.
References
- Andreux PA et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nature metabolism (2019). PMID 32694802
- Roberts KM et al. Dose-Dependent Increases in Ellagitannin Metabolites as Biomarkers of Intake in Humans Consuming Standardized Black Raspberry Food Products Designed for Clinical Trials. Molecular nutrition & food research (2020). PMID 32112501
- MartĂnez-Sánchez A et al. Consumption of Watermelon Juice Enriched in l-Citrulline and Pomegranate Ellagitannins Enhanced Metabolism during Physical Exercise. Journal of agricultural and food chemistry (2017). PMID 28513179
- Bizarelo R et al. Acid hydrolysis of jaboticaba (Myrciaria jaboticaba) peel and seed powder increases urolithin excretion in a cross-over clinical trial with normoweight subjects. Food & function (2026). PMID 42023516
- DomĂnguez-LĂłpez I et al. Urinary polyphenol signature of the Mediterranean diet is associated with lower cardiovascular disease risk: the PREDIMED trial. BMC medicine (2025). PMID 41408634
- Singh A et al. Urolithin A improves muscle strength, exercise performance, and biomarkers of mitochondrial health in a randomized trial in middle-aged adults. Cell reports. Medicine (2022). PMID 35584623
- Liu S et al. Effect of Urolithin A Supplementation on Muscle Endurance and Mitochondrial Health in Older Adults: A Randomized Clinical Trial. JAMA network open (2022). PMID 35050355
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.